Accès ouvert déclaré 2024 article

Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry

Xueyuan Guo, Juan Du, Yang Yang, Mingxing Wu, Wenchao Ou, Xuebin Han, Zhifang Wang, Jing Jin, Ping Zhang, Zheng Zhang, Guoqin Chen, Mingzhi Long, Yin Guotian, Tong Liu, Xiaoyan Wang, Dong‐Sheng Li, Manhua Chen, Yugang Dong, Chunlin Lai, Xuelian Zhang, Yi Yuan, Jing Xiang, Cathy Yi-Hsuan Chen, Martin Unverdorben, Changsheng Ma, Yuehui Yin, Heng Qi, Zhisheng Jia, Xiaojun Ji, Yuqing Zhang, Xue Liang, Bing Deng, Jieyun Liu, Juan Ma, Cangsang Song, Huifang Feng, Suxin Luo, Jingfeng Wang, Lun Li, Yongqi Xiao, Junyou Cui, Zheng Huang, Jiafu Wei, Jinfang Cheng, Haiyan Li, Jun Zhang, Weihong Jiang, Jie Liu, Xinwen Min, Peng Gao, Lianjun Gao, Zhouqing Huang, Ruxing Wang, Ying Li, Zebin Ye, Xubo Wang, Hengli Lai, Lihong Wang, Minli Zhang, Changqian Wang, Wei Mao, Xiaohua Chen, Zhirong Wang, Fang Liu, Xiaolin Xie, Zhenggui Xu, Bin Dong, Hesong Zeng, Jianqiang Peng, Lihua Zhang, Qingyan Zhao, Fucheng Liu, Caixia Guo, Lijiang Tang, Xianjin Li, Jing Zhou, Xinchun Yang, Xiaoshu Chen, Yajuan Liu, Tiebi Tong, Jian Liu, Meise Lin, B. Liu, Guosheng Fu, Weimin Wang, Qing Yang, Baopeng Tang, Boli Ran, Jianjiang Xu, Chun-lin Yin, Pingzhen Yang, Fujie Yang, Ming Bai, Jian Zhang

4Citations signalées, ce qui n’est pas une note de qualité

104Institutions déclarées

2Pays d’affiliation déclarés

Rattachement africain : cn, us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract Real-world data on effectiveness and safety of a single non-vitamin K antagonist oral anticoagulant in the Chinese population with atrial fibrillation (AF) are limited. This study reports characteristics of patients treated with edoxaban and factors associated with dosing patterns from routine care in China. ETNA-AF-China (NCT04747496) is a multicentre, prospective, observational study enrolling edoxaban-treated patients from four economic regions with a targeted 2-year follow-up. Of the 4930 patients with AF (mean age: 70.2 ± 9.5 years; male, 57.1%), the mean creatinine clearance (CrCl), CHA2DS2-VASc, and HAS-BLED scores were 71.2 mL/min, 2.9, and 1.6. Overall, 6.4% of patients were perceived as frail by investigators. Available label dose reduction criteria (N = 4232) revealed that 3278 (77.5%) patients received recommended doses and 954 (22.5%) non-recommended doses. Northeast (53.0%) and West (43.1%) regions had the highest prescriptions of 60 mg and 30 mg recommended doses, respectively. Non-recommended 30 mg doses were more frequently prescribed in patients with antiplatelet use and history of heart failure than recommended 60 mg. Multivariate analysis identified advanced age as the strongest associated factor with non-recommended doses. Frailty had the strongest association with 30 mg except for age, and history of TIA was the most relevant factor associated with 60 mg. In conclusion, patients in the ETNA-AF-China study were predominantly aged 65 years and older, had mild-to-moderate renal impairment and good label adherence. Advanced age was associated with non-recommended doses, with frailty most common for non-recommended 30 mg and a history of TIA for the non-recommended 60 mg dose.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry
Date Crossref: 02/02/2024
Éditeur: Springer Science and Business Media LLC
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Capital Medical University Department of Cardiology pays non établi dans la notice
Université ou école supérieure
Beijing Anzhen Hospital pays non établi dans la notice
Établissement de santé
Shenyang Medical College Department of Cardiology pays non établi dans la notice
Université ou école supérieure
Xiangyang Central Hospital pays non établi dans la notice
Établissement de santé
Second Affiliated Hospital of Guangzhou Medical University Department of Cardiology pays non établi dans la notice
Établissement de santé
Guangzhou Medical University pays non établi dans la notice
Université ou école supérieure
Shanxi Cardiovascular Hospital Department of Cardiology pays non établi dans la notice
Établissement de santé
Xinxiang Central Hospital Deparment of Vasculocardiology pays non établi dans la notice
Établissement de santé
Fourth Hospital of Changsha Department of Cardiology pays non établi dans la notice
Établissement de santé
Beijing Tsinghua Chang Gung Hospital pays non établi dans la notice
Établissement de santé
Fudan University Department of Cardiology pays non établi dans la notice
Université ou école supérieure
Zhongshan Hospital pays non établi dans la notice
Établissement de santé

Department of Cardiology — Capital Medical University, Beijing Anzhen Hospital et Department of Cardiology — Shenyang Medical College, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Atrial Fibrillation Management and OutcomesHealth Systems, Economic Evaluations, Quality of LifeAcute Ischemic Stroke Management

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI